Cargando…

Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines

BACKGROUND: Emerging evidence suggests heterologous prime-boost COVID-19 vaccination as a superior strategy than homologous schedules. Animal experiments and clinical observations have shown enhanced antibody response against influenza variants after heterologous vaccination; however, whether the in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yufang, Lu, Yingying, Zhou, Caili, Tong, Gangling, Gao, Manman, Zhan, Yan, Wang, Yan, Liang, Ran, Li, Yawei, Gao, Tianjiao, Wang, Li, Zhang, Muyun, Cheng, Jin, Gong, Jun, Wang, Jimin, Zhang, Wei, Qi, Junhua, Cui, Miao, Zhu, Longchao, Xiao, Fenglian, Zhu, Linyu, Xu, Yunsheng, Zheng, Zhihua, Zhou, Zhiyu, Cheng, Zhengjiang, Hong, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181311/
https://www.ncbi.nlm.nih.gov/pubmed/35679856
http://dx.doi.org/10.1016/j.medj.2022.05.003
_version_ 1784723739112374272
author Zhu, Yufang
Lu, Yingying
Zhou, Caili
Tong, Gangling
Gao, Manman
Zhan, Yan
Wang, Yan
Liang, Ran
Li, Yawei
Gao, Tianjiao
Wang, Li
Zhang, Muyun
Cheng, Jin
Gong, Jun
Wang, Jimin
Zhang, Wei
Qi, Junhua
Cui, Miao
Zhu, Longchao
Xiao, Fenglian
Zhu, Linyu
Xu, Yunsheng
Zheng, Zhihua
Zhou, Zhiyu
Cheng, Zhengjiang
Hong, Peng
author_facet Zhu, Yufang
Lu, Yingying
Zhou, Caili
Tong, Gangling
Gao, Manman
Zhan, Yan
Wang, Yan
Liang, Ran
Li, Yawei
Gao, Tianjiao
Wang, Li
Zhang, Muyun
Cheng, Jin
Gong, Jun
Wang, Jimin
Zhang, Wei
Qi, Junhua
Cui, Miao
Zhu, Longchao
Xiao, Fenglian
Zhu, Linyu
Xu, Yunsheng
Zheng, Zhihua
Zhou, Zhiyu
Cheng, Zhengjiang
Hong, Peng
author_sort Zhu, Yufang
collection PubMed
description BACKGROUND: Emerging evidence suggests heterologous prime-boost COVID-19 vaccination as a superior strategy than homologous schedules. Animal experiments and clinical observations have shown enhanced antibody response against influenza variants after heterologous vaccination; however, whether the inoculation order of COVID-19 vaccines in a prime-boost schedule affects antibody response against SARS-CoV-2 variants is not clear. METHODS: We conducted immunological analyses in a cohort of health care workers (n = 486) recently vaccinated by three types of inactivated COVID-19 vaccines under homologous or heterologous prime-boost schedules. Antibody response against ancestral SARS-CoV-2 (Wuhan-Hu-1) was assessed by total antibody measurements, surrogate virus neutralization tests, and pseudovirus neutralization assays (PNA). Furthermore, serum neutralization activity against SARS-CoV-2 variants of concern was also measured by PNA. FINDINGS: We observed strongest serum neutralization activity against the widely circulating SARS-CoV-2 variant B.1.617.2 among recipients of heterologous BBIBP-CorV/CoronaVac and WIBP-CorV/CoronaVac. In contrast, recipients of CoronaVac/BBIBP-CorV and CoronaVac/WIBP-CorV showed significantly lower B.1.617.2 neutralization titers than recipients of reverse schedules. Laboratory tests revealed that neutralizing activity against common variants but not the ancestral SARS-CoV-2 was associated with the inoculation order of heterologous prime-boost vaccines. Multivariable regression analyses confirmed this association after adjusting for known confounders. CONCLUSIONS: Our data provide clinical evidence of inoculation order-dependent expansion of neutralizing breadth against SARS-CoV-2 in recipients of heterologous prime-boost vaccination and call for further studies into its underlying mechanism. FUNDING: National Key R&D Program of China, National Development and Re-form Commission of China, National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Commission, and US Department of Veterans Affairs.
format Online
Article
Text
id pubmed-9181311
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-91813112022-06-10 Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines Zhu, Yufang Lu, Yingying Zhou, Caili Tong, Gangling Gao, Manman Zhan, Yan Wang, Yan Liang, Ran Li, Yawei Gao, Tianjiao Wang, Li Zhang, Muyun Cheng, Jin Gong, Jun Wang, Jimin Zhang, Wei Qi, Junhua Cui, Miao Zhu, Longchao Xiao, Fenglian Zhu, Linyu Xu, Yunsheng Zheng, Zhihua Zhou, Zhiyu Cheng, Zhengjiang Hong, Peng Med (N Y) Clinical and Translational Report BACKGROUND: Emerging evidence suggests heterologous prime-boost COVID-19 vaccination as a superior strategy than homologous schedules. Animal experiments and clinical observations have shown enhanced antibody response against influenza variants after heterologous vaccination; however, whether the inoculation order of COVID-19 vaccines in a prime-boost schedule affects antibody response against SARS-CoV-2 variants is not clear. METHODS: We conducted immunological analyses in a cohort of health care workers (n = 486) recently vaccinated by three types of inactivated COVID-19 vaccines under homologous or heterologous prime-boost schedules. Antibody response against ancestral SARS-CoV-2 (Wuhan-Hu-1) was assessed by total antibody measurements, surrogate virus neutralization tests, and pseudovirus neutralization assays (PNA). Furthermore, serum neutralization activity against SARS-CoV-2 variants of concern was also measured by PNA. FINDINGS: We observed strongest serum neutralization activity against the widely circulating SARS-CoV-2 variant B.1.617.2 among recipients of heterologous BBIBP-CorV/CoronaVac and WIBP-CorV/CoronaVac. In contrast, recipients of CoronaVac/BBIBP-CorV and CoronaVac/WIBP-CorV showed significantly lower B.1.617.2 neutralization titers than recipients of reverse schedules. Laboratory tests revealed that neutralizing activity against common variants but not the ancestral SARS-CoV-2 was associated with the inoculation order of heterologous prime-boost vaccines. Multivariable regression analyses confirmed this association after adjusting for known confounders. CONCLUSIONS: Our data provide clinical evidence of inoculation order-dependent expansion of neutralizing breadth against SARS-CoV-2 in recipients of heterologous prime-boost vaccination and call for further studies into its underlying mechanism. FUNDING: National Key R&D Program of China, National Development and Re-form Commission of China, National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Commission, and US Department of Veterans Affairs. Elsevier Inc. 2022-08-12 2022-06-09 /pmc/articles/PMC9181311/ /pubmed/35679856 http://dx.doi.org/10.1016/j.medj.2022.05.003 Text en © 2022 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Clinical and Translational Report
Zhu, Yufang
Lu, Yingying
Zhou, Caili
Tong, Gangling
Gao, Manman
Zhan, Yan
Wang, Yan
Liang, Ran
Li, Yawei
Gao, Tianjiao
Wang, Li
Zhang, Muyun
Cheng, Jin
Gong, Jun
Wang, Jimin
Zhang, Wei
Qi, Junhua
Cui, Miao
Zhu, Longchao
Xiao, Fenglian
Zhu, Linyu
Xu, Yunsheng
Zheng, Zhihua
Zhou, Zhiyu
Cheng, Zhengjiang
Hong, Peng
Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines
title Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines
title_full Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines
title_fullStr Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines
title_full_unstemmed Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines
title_short Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines
title_sort association of neutralizing breadth against sars-cov-2 with inoculation orders of heterologous prime-boost vaccines
topic Clinical and Translational Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181311/
https://www.ncbi.nlm.nih.gov/pubmed/35679856
http://dx.doi.org/10.1016/j.medj.2022.05.003
work_keys_str_mv AT zhuyufang associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT luyingying associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT zhoucaili associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT tonggangling associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT gaomanman associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT zhanyan associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT wangyan associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT liangran associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT liyawei associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT gaotianjiao associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT wangli associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT zhangmuyun associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT chengjin associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT gongjun associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT wangjimin associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT zhangwei associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT qijunhua associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT cuimiao associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT zhulongchao associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT xiaofenglian associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT zhulinyu associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT xuyunsheng associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT zhengzhihua associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT zhouzhiyu associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT chengzhengjiang associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines
AT hongpeng associationofneutralizingbreadthagainstsarscov2withinoculationordersofheterologousprimeboostvaccines